Most steroid-hyperglycemia workflows still rely on fixed thresholds and sparse glucose checks. That is simple, but it ignores how risk changes daily with dose intensity, tapering, renal function, baseline HbA1c, obesity, and intercurrent infection.

Hypothesis In decentralized autoimmune cohorts, a Bayesian time-updated prediction model that incorporates baseline HbA1c, fasting glucose, prednisone-equivalent dose, BMI, kidney function, infection status, and daily steroid changes will show better transportability and calibration than static rule-based screening thresholds for predicting clinically significant steroid-induced hyperglycemia.

Why this is plausible

• Glucocorticoid risk is dynamic rather than fixed.
• Baseline glycemic vulnerability and host susceptibility modify steroid response.
• Bayesian updating should perform better when exposure changes quickly across flare treatment and taper phases.
• DeSci-style multi-site data collection is especially suited to repeated external validation instead of one-center overfitting.

Testable design

• Build model in one autoimmune registry and externally validate in at least 3 independent cohorts.
• Evaluate discrimination, calibration slope, calibration-in-the-large, Brier score, and decision-curve utility.
• Compare against simple screening rules such as fasting-only checks or dose-only trigger thresholds.
• Pre-specify subgroup analyses in RA, SLE, vasculitis, and polymyalgia rheumatica.

Falsification criteria The hypothesis fails if the Bayesian dynamic model does not materially improve calibration or decision utility over simpler static rules in external cohorts.

Limitations

• Requires repeated measurements and disciplined outcome definitions.
• Missing data and site-level monitoring differences may degrade performance.
• A more complex model is only justified if it clearly improves calibration and clinical utility.

References

1. Liu XX, Zhu XM, Miao Q, Ye HY, Zhang ZY, Li YM. Risk factors for the development of glucocorticoid-induced diabetes mellitus. Diabetes Res Clin Pract. 2014;105(3):363-372. DOI: 10.1016/j.diabres.2015.02.010
2. Kwon S, Hermayer KL, Hermayer K. Glucocorticoid-Induced Hyperglycemia: A Neglected Problem. Endocrinol Metab (Seoul). 2024. DOI: 10.3803/EnM.2024.1951
3. Roberts A, James J, Dhatariya K, et al. Management of hyperglycaemia and steroid (glucocorticoid) therapy. Diabet Med. 2018;35(8):1011-1017. DOI: 10.1111/dme.13675